Quick Answer
Oruka Therapeutics, Inc. reported Stockholders Equity of $471.93 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed an increase of +23.5% in Stockholders Equity from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $10.28 million | Q1 2018: $11.05 million | Q2 2018: $9.00 million | Q3 2018: $7.46 million | Q1 2019: $7.32 million | Q2 2019: $9.19 million | Q3 2019: $8.80 million | Q1 2020: $6.31 million | Q2 2020: $10.31 million | Q3 2020: $50.46 million | Q1 2021: $65.91 million | Q2 2021: $61.21 million | Q3 2021: $56.60 million | Q1 2022: $47.94 million | Q2 2022: $44.96 million | Q3 2022: $42.73 million | Q4 2022: $41.67 million | Q1 2023: $40.53 million | Q2 2023: $39.24 million | Q3 2023: $37.97 million | Q4 2023: $37.02 million | Q1 2024: -$7.06 million | Q2 2024: -$28.98 million | Q3 2024: $342.37 million | Q1 2025: $364.73 million | Q2 2025: $343.64 million | Q3 2025: $486.79 million.
- Over the full 19 years of available data (2008 to 2025), Oruka Therapeutics, Inc.'s Stockholders Equity has grown by 1,336.1%.
- Historical annual values: Fiscal year 2025: $471.93 million | Fiscal year 2024: $382.22 million | Fiscal year 2024: $1.0 thousand | Fiscal year 2023: $37.02 million | Fiscal year 2022: $41.67 million | Fiscal year 2021: $51.04 million | Fiscal year 2020: $46.52 million | Fiscal year 2019: $7.61 million | Fiscal year 2018: $6.03 million | Fiscal year 2017: $10.28 million | Fiscal year 2016: $22.19 million | Fiscal year 2015: $38.07 million | Fiscal year 2014: $14.74 million | Fiscal year 2013: $15.58 million | Fiscal year 2012: $2.91 million | Fiscal year 2011: $5.73 million | Fiscal year 2010: $6.77 million | Fiscal year 2009: $7.41 million | Fiscal year 2008: -$38.18 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: